Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VB119 in Primary MCD or FSGS
NCT05441826Phase 2Terminated
- Sponsor
- Tenet Medicines
- Start
- May 2022
- Primary completion
- May 2023
- Modality
- scFv Fragments, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of vb119 in minimal change disease (MCD), focal segmental glomerulosclerosis (FSGS), sponsored by Tenet Medicines. Started May 2022; status: terminated.
02
Drugs
vb119
03
Conditions
minimal change disease (MCD)focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on NCT05441826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05441826.